A 52-year-old woman with type 2 diabetes mellitus presents with an HbA1c of 8.2% despite metformin 1000 mg twice daily for six months. She is hypertensive (BP 148/92 mmHg, HR 88/min), overweight (BMI 31 kg/m²), and her fasting glucose today is 184 mg/dL. She adamantly refuses injectable medications and expresses concern about iatrogenic weight gain. Physical examination reveals no peripheral edema. She denies polyuria, polydipsia, and recent infections. Which oral incretin-based medication best aligns with her clinical preferences and metabolic goals?
- A)Semaglutide
- B)NPH insulin
- C)SitagliptinGABARITO
- D)Glyburide
- E)Pioglitazone
Explicação
Sitagliptin is an oral DPP 4 inhibitor that increases endogenous incretin activity and is generally weight neutral. In contrast, semaglutide is a GLP 1 receptor agonist that often promotes greater weight loss but is commonly delivered by injection. Ver explicação completa e trilha adaptativa →